Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Изучение эффективности, безопасности и фармакокинетики CPL500036 (ингибитора ФДЭ10А) у пациентов с шизофренией

10 ноября 2026 г. обновлено: Celon Pharma SA

Фаза II, двойное слепое, рандомизированное, плацебо-контролируемое, параллельная группа, испытание для изучения эффективности, безопасности и фармакокинетики CPL500036 (ингибитора ФДЭ10А) у пациентов с острым обострением шизофрении

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..

Обзор исследования

Статус

Завершенный

Условия

Подробное описание

This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.

Тип исследования

Интервенционный

Регистрация (Действительный)

189

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Budapest, Венгрия, H-1083
        • Department of Psychiatry and Psychotheraapy of Semmelweis University
      • Budapest, Венгрия, H-1085
        • Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
      • Győr, Венгрия, H-9024
        • Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
      • Kalocsa, Венгрия, H-6300
        • Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
      • Szekszárd, Венгрия, H-7100
        • Psychiatry Department of Tolna County Balassa Janos Hospital
      • Bialystok, Польша, 15-272
        • Uniwersytecki Szpital Kliniczny
      • Bolesławiec, Польша, 59-700
        • Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
      • Choroszcz, Польша, 16-070
        • Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
      • Gmina Świecie, Польша, 86-100
        • Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
      • Ivano-Frankivsk, Украина, 76014
        • Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
      • Kyiv, Украина, 04080
        • Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
      • Kyiv, Украина, 08631
        • Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
      • Lviv, Украина, 79017
        • Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
      • Lviv, Украина, 79021
        • Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
      • Ternopil, Украина, 46001
        • Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
      • Vinnytsia, Украина, 21018
        • Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 65 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].
  2. Male or female patient aged 18 to 65, inclusive, at Screening.
  3. The patient's with exacerbation of psychotic symptoms
  4. The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
  5. The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
  6. The patient of childbearing potential willing to use acceptable forms of contraception.
  7. The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
  8. The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
  9. The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Exclusion Criteria:

  1. The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
  2. Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
  3. The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
  4. The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
  5. The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
  6. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
  7. The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
  8. The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
  9. The patient has chronic movement disorder that may interfere with the interpretation of study results.
  10. The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
  11. The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
  12. The patient is considered to be treatment resistant. .
  13. The patient has received electroconvulsive therapy.
  14. The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: CPL500036 low dose

Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.

CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.

Экспериментальный: CPL500036 high dose

Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.

CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.

Плацебо Компаратор: Placebo

Patients are to receive placebo administered once dail for 28-days treatment period.

Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline in PANSS Positive Subscale at Week 4.
Временное ограничение: Day -1, Week 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 4

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline in PANSS Positive Subscale at Week 1, 2 and 3
Временное ограничение: Day -1, Week 1, 2 and 3

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2 and 3
Change From Baseline in PANSS Total Score at Weeks 1, 2, 3, 4
Временное ограничение: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS Subscales Using the Marder 5 Factor Model at Weeks 1, 2, 3, and 4
Временное ограничение: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) Marder 5-Factor Model is a structure used for the Positive and Negative Syndrome Scale (as original PANSS scale), but breaking its 30 items (from positive, negative and general psychopathology groups) into five key symptom domains: Positive (8 items: Range 8-56), Negative (7 items: Range 7-49), Disorganized thoughts (7 items: Range 7-49), Uncontrolled hostility/excitement (4 items: Range 4-28), and Anxiety/depression (4 items: Range 4-28). The higher score in subscale, the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4
Временное ограничение: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS General Psychopathology Subscale at Weeks 1, 2, 3 and 4
Временное ограничение: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Percentage of Clinical Responders Based on the PANSS Total Score.
Временное ограничение: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Clinical responder is defined as a ≥ 30% decrease from baseline.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4
Временное ограничение: Day -1, Week 1, 2, 3 and 4

CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients.

Day -1, Week 1, 2, 3 and 4
Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.
Временное ограничение: Day -1, Week 1, 2, 3 and 4

CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse

Day -1, Week 1, 2, 3 and 4
Percentage of Clinical Responders Based on the CGI-I Score.
Временное ограничение: Day -1, Week 1, 2, 3 and 4
Day -1, Week 1, 2, 3 and 4
Change From Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) T-Score at Weeks 2 and 4.
Временное ограничение: Day -1, Week 2 and 4

Brief Assessment Cognition in Schizophrenia (BACS) is specifically designed to measure treatment-related improvements in cognition. A BACS T-score indicating cognitive performance of patients with schizophrenia with a mean of 50 and SD of 10, used for evaluating brain function. Scores are standardized, compared a person's with cognition impairment to a normative group, with scores below 50 indicating poorer performance (lower scores suggest greater difficulty) and above 50 better.

Day -1, Week 2 and 4
Number of Abnormal Physical, Neurological, Ophthalmological and Dermatological Examination Findings.
Временное ограничение: up to 6 weeks
up to 6 weeks
Number of Adverse Events.
Временное ограничение: up to 6 weeks

All adverse events that occurence during study were assessed.

up to 6 weeks
Number of Abnormal Clinically Significant Values in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate) Results.
Временное ограничение: up to 6 weeks
up to 6 weeks
Number of Abnormal Clinically Significant Values in Laboratory Tests (Hematologic, Clinical Chemistry, Coagulation and Urinalysis) Results.
Временное ограничение: up to 6 weeks
up to 6 weeks
Number of Abnormal Clinically Significant Findings in Electrocardiogram Results.
Временное ограничение: up to 6 weeks

The following electrocardiogram parameters were assessed: PR interval, QRS interval, RR interval, QT interval and QTc interval.

up to 6 weeks
Number and Intensity of Extrapyramidal Side Effects.
Временное ограничение: up to 6 weeks

It was assessed by Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia.

up to 6 weeks

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

19 мая 2021 г.

Первичное завершение (Действительный)

5 июня 2024 г.

Завершение исследования (Действительный)

19 июня 2024 г.

Даты регистрации исследования

Первый отправленный

9 февраля 2022 г.

Впервые представлено, что соответствует критериям контроля качества

3 марта 2022 г.

Первый опубликованный (Действительный)

14 марта 2022 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

12 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

10 ноября 2026 г.

Последняя проверка

1 сентября 2025 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 02PDE2019

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться